M&A Deal Summary

Juno Therapeutics Acquires AbVitro

On January 11, 2016, Juno Therapeutics acquired information technology company AbVitro for 78M USD

Acquisition Highlights
  • This is Juno Therapeutics’ 1st transaction in the Information Technology sector.
  • This is Juno Therapeutics’ largest (disclosed) transaction.
  • This is Juno Therapeutics’ 2nd transaction in the United States.
  • This is Juno Therapeutics’ 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2016-01-11
Target AbVitro
Sector Information Technology
Buyer(s) Juno Therapeutics
Deal Type Add-on Acquisition
Deal Value 78M USD

Target

AbVitro

Boston, Massachusetts, United States
website
AbVitro, Inc. is a provider of technology platform accelerates the development of novel immunotherapies by identifying cancer-specific immune cells from natural immune responses at unprecedented resolution.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Juno Therapeutics

Seattle, Washington, United States

website

Category Company
Founded 2013
Sector Life Science
Employees373
Revenue 18M USD (2015)
DESCRIPTION

Juno Therapeutics, Inc. is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Juno Therapeutics was founded in 2013 and is based in Seattle, Washington.

DEAL STATS #
Overall 3 of 4
Sector (Information Technology) 1 of 1
Type (Add-on Acquisition) 3 of 4
State (Massachusetts) 2 of 3
Country (United States) 2 of 3
Year (2016) 1 of 2
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-02 X-BODY

Waltham, Massachusetts, United States

X-BODY, Inc. is a biotechnology company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-14 RedoxTherapies

Boston, Massachusetts, United States

RedoxTherapies, Inc. is an adenosine research company. Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors.

Buy $10M
Mergr

Product

Company

Legal